Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC

This is a Phase I/Ib trial, single-center, non-randomized, open-label study of Protein-bound Paclitaxel, Cisplatin, And Gemcitabine (GCN) Combined with Tumor Treatment Fields (TTF) and G+TTF maintenance therapy in patients with metastatic pancreatic cancer.

Trial Details

NCT ID
NCT04605913
Phase
PHASE1 / PHASE2
Sponsor
Mayo Clinic
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Modified GCN+TTF treatment
Locations (sample)
  • Jacksonville, Florida, United States|30.33218,-81.65565

Key Eligibility Criteria

  • Histologically or cytologically confirmed pancreatic adenocarcinoma or adeno-squamous carcinoma with liver metastasis.
  • Subjects with additional sites of metastasis, except known brain metastasis, are eligible.
  • Histologies excluded include squamous, small cell carcinoma, and acinar cell carcinoma. However, adeno-squamous histology can be enrolled.
  • Patients who have recurrence or metastasis after surgery and adjuvant therapy do not need repeat biopsy for confirmation of recurrence if clinical …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →